CD38 and Miyoshi myopathy: Nevertheless, future preclinical and clinical studies will determine the best time schedule for the administration of tinostamustine and daratumumab or other anti-CD38 mAbs, as well as a more precise positioning of these combinations within the existing therapy landscape of MM.